RPTX (Repare Therapeutics) Long-Term Debt: $0.00 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RPTX Repare Therapeutics Inc RPTX
20 GF Score
Price $2.65
GF Value $0.94
! 6 Warning Signs
View Full Analysis

What is Repare Therapeutics Long-Term Debt?

Repare Therapeutics RPTX 20 Long-Term Debt is $0.00 Mil as of Sep. 2025. GuruFocus rates RPTX with a GF Score™ of 20/100 and a GF Value™ of $0.94. The stock has 6 warning signs investors should review.

Repare Therapeutics's Long-Term Debt for the quarter that ended in Sep. 2025 was $0.00 Mil.

Repare Therapeutics  (NAS:RPTX) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Repare Therapeutics Long-Term Debt Related Terms

Repare Therapeutics Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Repare Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Repare Therapeutics Long-Term Debt Chart

Repare Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Long-Term Debt
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Repare Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
RPTX
20GF Score
Repare Therapeutics Inc RPTX
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.00 Mil mean?
Repare Therapeutics (RPTX) has a Long-Term Debt of $0.00 Mil as of Sep. 2025.
Is Repare Therapeutics' Long-Term Debt too high?
Repare Therapeutics' current Long-Term Debt is $0.00 Mil. Overall, Repare Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Repare Therapeutics' Long-Term Debt compare to MGNX and THAR?
Repare Therapeutics' Long-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Repare Therapeutics's current Long-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Repare Therapeutics stock overvalued right now?
Repare Therapeutics (RPTX) has a current Long-Term Debt of $0.00 Mil. The stock's GF Value™ is $0.94, compared to a current price of $2.65 — trading 181.9% above its estimated fair value. The current Long-Term Debt is $0.00 Mil. Repare Therapeutics' overall GF Score™ is 20/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Repare Therapeutics (RPTX), the current Long-Term Debt is $0.00 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Repare Therapeutics (RPTX) Overvalued in 2026?

Based on GuruFocus' analysis, Repare Therapeutics stock appears to be overvalued. The current stock price of $2.65 is trading 181.9% above its estimated GF Value™ of $0.94.

Key valuation signals for RPTX:

  • Long-Term Debt: $0.00 Mil
  • GF Value™: $0.94 vs. price of $2.65 (181.9% above fair value)
  • GF Score™: 20/100 with 6 warning signs

No single metric tells the full story. See the RPTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Repare Therapeutics Business Description

Address 7210 Frederick-Banting Street, Suite 100, Saint-Laurent, QC, CAN, H4S 2A1
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
20GF Score

Get the complete analysis for RPTX

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.65
Price
$0.94
GF Value